Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Julie Napieralski"'
Autor:
Jerry S. Wolinsky, Harold Köndgen, Ludwig Kappos, Michael K. Racke, Laura Julian, Lori Mayer, Carrie Li, Hanzhe Zheng, Stephen L. Hauser, Anthony Traboulsee, Kottil Rammohan, Julie Napieralski
Publikováno v:
Multiple Sclerosis and Related Disorders. 30:236-243
Background Ocrelizumab is an infusible humanized monoclonal antibody that selectively depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the OPERA I, OPERA II, and ORATORIO trials for relapsing and primary progressive mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9773b02be92ab847d5ce56e94d88c523
https://doi.org/10.1016/j.msard.2019.01.044
https://doi.org/10.1016/j.msard.2019.01.044
Publikováno v:
Actualités Pharmaceutiques. 60:34-35
La crise sanitaire a incontestablement joue un role de catalyseur pour la telesante. Le developpement des e-consultations permet deja de repondre a des problematiques de desertification medicale. Les etudiants en pharmacie ont publie une contribution
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f3b51fe7401fbcd0c95af10c8e899fa
https://doi.org/10.1016/j.actpha.2021.03.031
https://doi.org/10.1016/j.actpha.2021.03.031
Autor:
Julie, Napieralski
Publikováno v:
Actualites Pharmaceutiques
La crise sanitaire aura bouleversé le fonctionnement de notre société et nous aura marqués individuellement. Dès que la fermeture des universités a été décidée, les étudiants en pharmacie ont su que leur quotidien ne serait plus le même.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3ab43b026dacb62c05ad536a7bb72419
https://pubmed.ncbi.nlm.nih.gov/33100499
https://pubmed.ncbi.nlm.nih.gov/33100499
Autor:
Ségolène Vivares, Julie Napieralski
Publikováno v:
Actualités Pharmaceutiques. 59:40-41
Les etudes de sante imposent un rythme intense et sont particulierement longues. Les etudiants en pharmacie sont confrontes a de nombreuses difficultes qui mettent en peril leur sante et parfois la poursuite de leur cursus. Des initiatives doivent et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e86f1b2501754b3984a19c17387f4d7e
https://doi.org/10.1016/j.actpha.2020.09.016
https://doi.org/10.1016/j.actpha.2020.09.016
Autor:
Julie Napieralski
Publikováno v:
Actualités Pharmaceutiques
francaisLa crise sanitaire aura bouleverse le fonctionnement de notre societe et nous aura marques individuellement. Des que la fermeture des universites a ete decidee, les etudiants en pharmacie ont su que leur quotidien ne serait plus le meme. Nomb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dfca00c550cdc1269780c2a1e3645ff
https://doi.org/10.1016/j.actpha.2020.08.012
https://doi.org/10.1016/j.actpha.2020.08.012
Autor:
Laura Julian, Jian Han, Frederik Barkhof, Shibeshih Belachew, Hans-Peter Hartung, Annette Sauter, Amit Bar-Or, Jerry S. Wolinsky, Ludwig Kappos, David K.B. Li, Stephen L. Hauser, Harold Koendgen, Julie Napieralski
Publikováno v:
Neurology, 93(19), e1778-e1786. Lippincott Williams and Wilkins
Neurology
Neurology, vol 93, iss 19
Barkhof, F, Kappos, L, Wolinsky, J S, Li, D K B, Bar-Or, A, Hartung, H-P, Belachew, S, Han, J, Julian, L, Sauter, A, Napieralski, J, Koendgen, H & Hauser, S L 2019, ' Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis ', Neurology, vol. 93, no. 19, pp. e1778-e1786 . https://doi.org/10.1212/WNL.0000000000008189, https://doi.org/10.1212/WNL.0000000000008189
Neurology
Neurology, vol 93, iss 19
Barkhof, F, Kappos, L, Wolinsky, J S, Li, D K B, Bar-Or, A, Hartung, H-P, Belachew, S, Han, J, Julian, L, Sauter, A, Napieralski, J, Koendgen, H & Hauser, S L 2019, ' Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis ', Neurology, vol. 93, no. 19, pp. e1778-e1786 . https://doi.org/10.1212/WNL.0000000000008189, https://doi.org/10.1212/WNL.0000000000008189
ObjectiveTo assess the onset of ocrelizumab efficacy on brain MRI measures of disease activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled phase III studies in relapsing multiple sclerosis (R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5396b1c1236d5eba74d4ff1e18a9b80
https://research.vumc.nl/en/publications/21798927-942a-40fb-baa3-33f68e6feb3f
https://research.vumc.nl/en/publications/21798927-942a-40fb-baa3-33f68e6feb3f
Autor:
Julie Napieralski
Publikováno v:
Actualites Pharmaceutiques
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a72f139e1f508989ce63cbc04b2fb826
http://europepmc.org/articles/PMC7574687
http://europepmc.org/articles/PMC7574687
Autor:
Julie Napieralski
Publikováno v:
Actualites Pharmaceutiques
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d4f5ccc6cf855532af880cef0a67f6
http://europepmc.org/articles/PMC7331558
http://europepmc.org/articles/PMC7331558
Autor:
Eva Havrdova, Jian Han, Iain Bennett, Shibeshih Belachew, Giancarlo Comi, Douglas L. Arnold, Gavin Giovannoni, Ludwig Kappos, Anthony Traboulsee, Fred D. Lublin, Stephen L. Hauser, Regine Buffels, Laura Julian, Krzysztof Selmaj, Julie Napieralski, Hans-Peter Hartung, Amit Bar-Or, Hideki Garren
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Multiple sclerosis journal-experimental, translational and clinical, vol 4, iss 1
Multiple sclerosis journal-experimental, translational and clinical, vol 4, iss 1
Background No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4163fe9bce180cbe3804634231e6af7
http://europepmc.org/articles/PMC5858626
http://europepmc.org/articles/PMC5858626
Autor:
George Garibaldi, Henry A. Nasrallah, Rodrigo A. Bressan, Stephen R. Marder, Thomas Blaettler, Alice Wang, Stephen M. Lawrie, Dragana Bugarski-Kirola, Carol Reid, W. Wolfgang Fleischhacker, Julie Napieralski, Celso Arango, Mark Dixon, Tania Ochi-Lohmann
Publikováno v:
Biological psychiatry. 82(1)
Background There is currently no standard of care for treatment of negative symptoms of schizophrenia, although some previous results with glutamatergic agonists have been promising. Methods Three (SunLyte [WN25308], DayLyte [WN25309], and FlashLyte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e534915ddd2dac61060e0ba54af0cd79
https://pubmed.ncbi.nlm.nih.gov/28619253
https://pubmed.ncbi.nlm.nih.gov/28619253